Evidence Hub

Curcumin in pancreatic cancer: A comprehensive review of anticancer mechanisms, EMT modulation, and clinical challenges

Eftekhari H, Tajik Z, Ghafouri-Fard S

Cancer treatment and research communications, 2026

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive local invasion, early metastasis, and profound chemoresistance. Epithelial-mesenchymal transition (EMT) is a critical driver of these aggressive phenotypes, promoting tumor cell dissemination and therapeutic failure. Curcumin, a naturally occurring polyphenol derived from Curcuma longa, has emerged as a promising adjunctive agent due to its ability to modulate diverse molecular pathways, including those governing EMT.

Methods: In this review, we synthesized findings from published studies investigating the anti-EMT effects of curcumin and its analogs in PDAC. Data were extracted from in vitro, in vivo, and clinical studies, focusing on molecular mechanisms, signaling pathways, non-coding RNA networks, and therapeutic outcomes.

Results: Curcumin and its synthetic analogs suppress EMT in PDAC cells through multiple interconnected mechanisms, including inhibition of TGF-β/Smad, Hedgehog, PI3K/Akt/NF-κB, and IL-6/ERK/NF-κB signaling pathways. These effects are accompanied by upregulation of epithelial markers (E-cadherin) and downregulation of mesenchymal markers (vimentin, Snail, Slug), leading to reduced migration, invasion, and metastasis. Curcumin also modulates the tumor microenvironment by reversing the mesenchymal phenotype of cancer-associated fibroblasts and inhibiting stellate cell-induced EMT. A number of non-coding RNAs, including miRNAs…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free